ClinicalTrials.gg
DrugRead study by study

Elacestrant clinical trials

Also written RAD1901, ORSERDU and ER-306323.

studies test it
30
open now
19
in phase 3
4
first study started
2009
ClinicalTrials.gov finds 41 studies for elacestrant. How that becomes 30 here

Every study that search finds has been read, to see whether and how it gives elacestrant. ClinicalTrials.gov counts as of Nov 15, 2026. How drug pages count

  1. 41Found by its intervention search · See all 41 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 40 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
  2. +1Give it under a name that search misses: a biosimilar’s code or a misspelling
  3. 42Give elacestrant to participants
  4. −2Observe patients on it, or give it outside a trial
  5. −10Give it beside what is tested
  6. 30Test it: the count on this site

Get an email when these change. Save the elacestrant studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
27 Jan 2023 · ORSERDU · NDA 217639 (FDA, Drugs@FDA)
European Union
15 Sept 2023 · Orserdu · EMEA/H/C/005898 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Elacestrant
25
Elacestrant dihydrochloride
5

Brand

ORSERDU
4

Development codes

RAD1901
9
ER-306323
2
ASYM-122762
1

Studies by the year they started

30 studies that test it; most in 2026 (8)

Studies that test elacestrant, by start year
YearStudies
20091
20152
20161
20191
20211
20222
20236
20243
20255
20268

By phase

A phase 1/2 study counts in both.

Early Phase 1
1
Phase 1
8
Phase 2
22
Phase 3
4

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 12 · Other 18

Stemline Therapeutics, Inc. (9) · SOLTI Breast Cancer Research Group (2) · Radius Pharmaceuticals, Inc. (2) · Kristina A. Fanucci (2) · Jules Bordet Institute (1) · Jonsson Comprehensive Cancer Center (1) · Azienda Ospedaliero-Universitaria Careggi (1) · QuantumLeap Healthcare Collaborative (1)

Often tested with

Tested in the same studies.

Abemaciclib (2) · Letrozole (1) · Tamoxifen (1) · Everolimus (1) · Anastrozole (1) · Testosterone (1) · Endoxifen (1) · Palbociclib (1)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

New treatments tested with it · 4 most studied

New when their studies opened, with elacestrant beside them; studies of each.

Reaching primary completion within a year · 8

Studies that test elacestrant.

Studies

Open first, then newest update. How each study uses elacestrant has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.

Testing it · 30

See all 30 studies that test elacestrant →

Behind its US label · 1 — the studies the FDA label of ORSERDU describes

From the Clinical Studies section of ORSERDU (2026-06), as openFDA has it. A study the site does not hold is left out.

Tested on its own · 15 — no other medicine in its arm
Tested with established drugs · 7 — they are given beside it
Tested in a combination · 8 — another drug in the study is under test too
Beside an established treatment under test · 1 — an approved drug, surgery or radiation is what the study tests

Tested with elacestrant: Everolimus 1

Beside a new treatment under test · 7 — a new drug, cell therapy or vaccine is what the study tests

New treatments tested with elacestrant: onapristone 2 · samuraciclib 1 · KAT6 Inhibitor MEN2312 1 · RAD140 1

One option of several · 2 — a test or a strategy chooses among drugs
Observed · 2 — patients on it are followed, or it is given outside a trial

Codes

What other systems call elacestrant · ClinicalTrials.gg INT000889

  • MeSH (NLM) C000626176elacestrantConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) FM6A2627A8ELACESTRANTConfirmed FDA, NLM, Wikidata
  • Wikidata Q27278069elacestrantConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C120211ElacestrantOne source FDA
  • DrugBank DB06374One source Wikidata

Also registered as elacestrant hydrochloride (UNII 8NZT0PR8AL).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.

Start the discussion